-
Pfizer's new crown vaccine stimulates a strong immune response in adolescents and has a preventive effect of 100%
Time of Update: 2021-04-24
Today, Pfizer and BioNTech jointly announced that the new crown vaccine BNT162b2 jointly developed by the two parties has shown 100% efficacy and a strong antibody immune response in a phase 3 clinical trial conducted in adolescents aged 12-15.
-
Talking about: Sulfonate Drugs & Sulfonate Gene Toxicity
Time of Update: 2021-04-24
WenJohnsonIn recent years, the review of genetic toxic substances by the drug review department has become stricter and more demanding. Are genotoxic substances detected? What is the potential risk?
-
Hengrui Medicine HR19042 capsule was approved for clinical use in the treatment of primary IgA nephropathy
Time of Update: 2021-04-24
On December 31, 2020, Hengrui Medicine submitted a clinical trial application for this product to the National Food and Drug Administration for the treatment of primary IgA nephropathy.
-
Well-known top tertiary hospitals strictly check medical representatives!
Time of Update: 2021-04-24
At the same time, the medical representative filing management measures stipulate that medical representatives shall not perform the following behaviors: conduct academic promotion and other activities without filing; undertake drug sales tasks, implement sales activities such as collecting payments and processing purchase and sales receipts; participate in the statistics of the number of drug prescriptions issued by individual doctors, etc.
-
Acadi blockbuster dementia drug Nuplazid rejected by FDA
Time of Update: 2021-04-24
And Acadia pointed out that they had previously reached an agreement with the psychiatric research department supervised by Billy Dunn on the design of the drug’s key phase 3 clinical study HARMONY, which is aimed at analyzing as a single group A broad population of DRP patients.
-
Roche's new indication of ``Eimerizumab'' will be approved soon
Time of Update: 2021-04-24
According to the public information of the prior priority review, the indications that will be approved this time are: routine preventive treatment for adults and children with hemophilia A (congenital factor VIII deficiency) without clotting factor VIII inhibitors.
-
Kelun Pharmaceutical's Propofol Fumarate Tenofovir Tablets Obtained Drug Registration Certificate
Time of Update: 2021-04-24
On April 13, Kelun Pharmaceuticals issued an announcement stating that the company had recently obtained the "Drug Registration Certificate" for the chemical drug "Propofol Fumarate Tenofovir Tablets" approved and issued by the National Medical Products Administration.
-
Eli Lilly/GSK/Vir jointly announces expanded Phase 2 BLAZE-4 test top-line data
Time of Update: 2021-04-24
In addition, in terms of the key virological secondary endpoint of the new coronavirus (SARS-CoV-2) viral load from baseline inspection to the average change on days 3, 5, and 7, compared with placebo, the combination of bamlanivimab and VIR-7831 The use of the drug resulted in a statistically significant reduction in viral load.
-
CStone's new indications for RET inhibitors are planned to be included in priority review
Time of Update: 2021-04-24
" This time, prati The new indications for which the CDE is included in the application for priority review are: for the treatment of patients with advanced or metastatic RET-mutant medullary thyroid cancer in adults and children 12 years of age and older who require systemic treatment, as well as the need for systemic treatment.
-
Langlai Technology's IRAK4 inhibitor MY004 clinical trial application was accepted by NMPA
Time of Update: 2021-04-24
The purpose of the clinical study of MY004 application acceptance is to explore the safety, tolerability and pharmacokinetic properties of the drug in healthy subjects.
-
Hisun Pharmaceutical's tigecycline for injection passed the consistency evaluation
Time of Update: 2021-04-24
On November 21, 2018, the State Food and Drug Administration accepted the application for consistency evaluation of tigecycline for injection submitted by Hisun Pharmaceutical.
Up to now, Hisun Pharmaceuticals has invested about 9,730,300 yuan in the quality and efficacy consistency evaluation of the generic drug.
-
Xianju Pharmaceutical Receives Acceptance Notice for Consistency Evaluation of Dexamethasone Sodium Phosphate Injection
Time of Update: 2021-04-24
On April 6, Xianju Pharmaceutical issued an announcement stating that it had recently received a notice of acceptance of the consistency evaluation of dexamethasone sodium phosphate injection issued by the State Food and Drug Administration.
-
Where does the original research drug go?
Time of Update: 2021-04-24
Coincidentally, not long ago, Eli Lilly China announced internal adjustments to the sales and regional marketing team of Enpagliflozin (trade name: Ou Tangjing), as well as duloxetine hydrochloride (trade name: Xinbaida) and tadala.
-
Ding Xueguo, general manager of unnamed medicine, resigns
Time of Update: 2021-04-24
On April 11, Weiming Pharmaceutical issued an announcement stating that the board of directors had received a letter from the chairman of the company regarding Ding Xueguo's resignation as the general manager of the company.
At this point, Ding Xueguo will no longer hold the post of general manager of Xiamen Weiming Biomedical Co.
-
Announcement of audit results of pharmaceutical companies!
Time of Update: 2021-04-24
, Ltd. The inspection found that the company had the following problems: First, its affiliated Xinyi Pharmaceutical Business Department inflated travel expenses of RMB 20,033,600 in 2018, which were listed as fueling invoices, but could not provide details of the recharge card number, expense approval form and other information.
-
Starting from April, pharmaceutical companies that have not submitted a letter of trust will not be able to participate in new bids or online appeals!
Time of Update: 2021-04-24
In accordance with the requirements of the National Medical Insurance Administration, starting from April 1st, for pharmaceutical companies that have not submitted a "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment", the provincial centralized procurement agencies will no longer accept their new bids or online appeals.
-
How to Train Your Dragon: TG6002
Time of Update: 2021-04-24
The design concept of chemotherapeutic drugs like 5-FU is to simply kill tumor cells that replicate faster, but the actual working mechanism is more complicated.
Therefore, in addition to selectively killing tumor cells, oncolytic viruses have a more important purpose for immune activation.
-
How do Qilu and Yilian Biopharmaceuticals add next-generation ADC drugs?
Time of Update: 2021-04-24
ADC drugs are mainly composed of three parts: antibody, linker (Linker) and cytotoxic drug (Payload), but the development of a successful ADC drug is by no means a simple addition, but an organic result of adjustment and optimization of each component.
-
Increase the black frame warning!
Time of Update: 2021-04-24
Since parenteral administration of aminoglycoside drugs has ototoxicity and nephrotoxicity, and the safety of treatment for more than 14 days has not been determined, patients receiving such drugs should be closely clinically observed.
-
Pien Tze Huang chairman Liu Jianshun resigns after retirement
Time of Update: 2021-04-24
On April 8, Pien Tze Huang issued an announcement stating that the board of directors had recently received a written resignation report from Chairman Liu Jianshun. Due to personal health reasons, Liu
